SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer

Abstract Background: SOX17 belongs to the high-mobility group-box transcription factor superfamily and down-regulates the Wnt pathway. The aim of our study was to evaluate the prognostic significance of SOX17 promoter methylation in circulating tumor DNA (ctDNA) in plasma of non-small cell lung cancer (NSCLC) patients. Methods: We examined the methylation status of SOX17 promoter in 57 operable NSCLC primary tumors and paired adjacent non-cancerous tissues and in ctDNA isolated from 48 corresponding plasma samples as well as in plasma from 74 patients with advanced NSCLC and 49 healthy individuals. SOX17 promoter methylation was examined by Methylation Specific PCR (MSP). Results: In operable NSCLC, SOX17 promoter was fully methylated in primary tumors (57/57, 100%), and in corresponding ctDNA (27/48, 56.2%) while it was detected in only 1/49 (2.0%) healthy individuals. In advanced NSCLC, SOX17 promoter was methylated in ctDNA in 27/74 (36.4%) patients and OS was significantly different in favor of patients with non-methylated SOX17 promoter (p=0.012). Multivariate analysis revealed that SOX17 promoter methylation in ctDNA was an independent prognostic factor associated with OS in patients with advanced but not operable NSCLC. Conclusions: Our results show that SOX17 promoter is highly methylated in primary tumors and in corresponding plasma samples both in operable and advanced NSCLC. In the advanced setting, SOX17 promoter methylation in plasma ctDNA has a statistical significant influence on NSCLC patient’s survival time. Detection of SOX17 promoter methylation in plasma provides prognostic information and merits to be further evaluated as a circulating tumor biomarker in patients with operable and advanced NSCLC.

[1]  D. Stewart,et al.  Review Wnt Signaling Pathway in Non–small Cell Lung Cancer Overview of the Wnt Canonical (β-catenin) and Noncanonical Signaling Pathways , 2022 .

[2]  Aaron M. Zorn,et al.  Sox17 and Sox4 Differentially Regulate β-Catenin/T-Cell Factor Activity and Proliferation of Colon Carcinoma Cells , 2007, Molecular and Cellular Biology.

[3]  Marius Žemaitis,et al.  Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. , 2007, Lung cancer.

[4]  E. Lianidou,et al.  Circulating tumor cells as promising novel biomarkers in solid cancers , 2014, Critical reviews in clinical laboratory sciences.

[5]  R. Rosenfeld.  Patients , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[6]  Peter Goodfellow,et al.  A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes , 1990, Nature.

[7]  Jun Wang,et al.  Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients , 2015, Breast Cancer Research and Treatment.

[8]  Georgia Sotiropoulou,et al.  DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. , 2011, Clinical chemistry.

[9]  Brett W Carter,et al.  Small cell lung carcinoma: staging, imaging, and treatment considerations. , 2014, Radiographics : a review publication of the Radiological Society of North America, Inc.

[10]  Hisao Asamura,et al.  The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  Diane D. Liu,et al.  Value of p16INK4a and RASSF1A Promoter Hypermethylation in Prognosis of Patients with Resectable Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[12]  Y. Lo,et al.  Clinical applications of maternal plasma fetal DNA analysis: translating the fruits of 15 years of research. , 2013, Clinical chemistry and laboratory medicine.

[13]  R. McCormack,et al.  Gefitinib Treatment in EGFR Mutated Caucasian NSCLC , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  J. Herman,et al.  Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. , 2008, Cancer research.

[15]  P. Bunn,et al.  Recent clinical advances in lung cancer management. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Zorzetto,et al.  EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells , 2013, Journal of Cancer Research and Clinical Oncology.

[17]  L. Bryzgalov,et al.  Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients. , 2013, Lung cancer.

[18]  E. Lianidou,et al.  SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. , 2013, Clinical chemistry.

[19]  M. Taketo,et al.  Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. , 2009, Gastroenterology.

[20]  G. Giaccone,et al.  American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Hoon,et al.  Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients , 2013, Expert review of molecular diagnostics.

[22]  R. McCormack,et al.  First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study , 2013, British Journal of Cancer.

[23]  J. Herman,et al.  Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. , 2011, Cancer discovery.

[24]  M. Ranson,et al.  Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours , 2010, The HUGO Journal.

[25]  C. Paweletz,et al.  Realizing the potential of plasma genotyping in an age of genotype-directed therapies. , 2014, Journal of the National Cancer Institute.

[26]  J. Coebergh,et al.  Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Marius Ilie,et al.  Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? , 2014, Annals of translational medicine.

[28]  Yin Rong,et al.  The Prognostic Value of Epigenetic Silencing of p16 Gene in NSCLC Patients: A Systematic Review and Meta-Analysis , 2013, PloS one.

[29]  E. Chatzaki,et al.  Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival , 2013, Clinical chemistry and laboratory medicine.

[30]  A. Schneeweiss,et al.  Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis , 2014, Breast Cancer Research and Treatment.

[31]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[32]  E. Lianidou,et al.  Asymmetric real-time PCR detection of BRCA1 5382insC mutation by melting curve analysis in the LightCycler. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[33]  D. Welch,et al.  Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer , 2014, British Journal of Cancer.

[34]  N. Auger,et al.  Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer , 2014, Front. Oncol..

[35]  D. Hoon,et al.  Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer , 2015, Expert review of molecular diagnostics.

[36]  K. Nie,et al.  Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer , 2014, Tumor Biology.

[37]  T. Liloglou,et al.  Lung cancer epigenetics: emerging biomarkers. , 2013, Biomarkers in medicine.

[38]  V. Georgoulias,et al.  A rapid and accurate closed-tube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[39]  Z. Shao,et al.  Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer , 2010, Breast Cancer Research and Treatment.